Search

Displaying results 1871 - 1880 of 10000 in total
  1. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [A265040,A265045] It works by targeting B-cell-specific CD19 surface markers present on malignant B cells. … [L52450] Obecabtagene autoleucel was also investigated in other hematological cancers and systemic lupus erythematosus.[A265045]

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING
  2. Drug

    Modafinil

    go.drugbank.com/drugs/DB00745
    ApprovedInvestigational

    The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.

  3. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy. … Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.

  4. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection … It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  5. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]

  6. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

  7. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    It is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair.

  8. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    It was approved for use in Japan in 1995.

  9. Drug

    Bendazac

    go.drugbank.com/drugs/DB13501
    ApprovedWithdrawn

    Bendazac is an oxyacetic acid [A39863, A39869]. … the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863.

  10. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection. … adults who are virologically suppressed on a stable antiretroviral regimen.